Pharmaceutical industry regulations and vaccine manipulation discussed by retired expert in interview.
-
Interview with retired pharmaceutical regulator Susan Lang • 0:37
-
Dr. Philip McMillan interviewing industry experts and critical minds • 1:22
-
Susan’s 40-year career in biotech, regulatory work, and consulting • 3:01
-
Susan’s expertise and insight into pandemic and vaccines • 3:37
-
Susan’s outspoken nature and reasons for speaking out • 4:12
-
Lack of industry insiders speaking out about regulations • 4:20
-
Susan’s lack of fear for job and career, and her outspoken nature • 4:36
Manipulation of Covid vaccine regulations and mRNA vaccine technology.
Regulatory concerns around mRNA vaccines and gene therapy, including changes in definition and consistency of manufacture.
-
mRNA vaccines regulated as gene therapy, not traditional vaccines • 9:33
-
Regulatory definition changed before pandemic, possibly influenced by pharmaceutical companies • 10:40
-
Concerns about unpredictability of individual body response to modified RNA • 12:19
-
Consistency of manufacture and potency a major issue in vaccine regulation • 13:07
Concerns about Covid vaccine regulations and development process in the pharmaceutical industry.
-
Concerns raised about vaccine development process and regulations • 13:34
-
Uncertainty about the manufacturing of antigens in the body • 13:45
-
Lack of studies on cell efficiency and potential drug interactions • 13:53
-
Regulatory bypass for genetic therapy categorized as vaccines • 14:25
-
Comparison of current vaccine development to traditional process • 15:06
-
Challenges in shortening clinical trial timelines • 16:28
-
Importance of animal studies and phased clinical trials in traditional vaccine development • 16:36
Concerns raised about vaccine regulations and long-term effects, lack of mitigation strategies, and trust in the medical industry.
Concerns raised about Covid vaccine regulations, including potential manipulation by pharmaceutical industry.
-
Urgent need for mainstream media coverage to address the impact on global health • 20:59
-
Advocacy for reverting to old technology vaccines to restore trust and address vaccine hesitancy • 21:38
-
Call for accountability within regulatory agencies and potential legal action against corrupt individuals • 22:02
-
Recognition of the necessity of institutions while emphasizing the removal of corrupt individuals • 22:15
-
Instances of bribery and blackmail within regulatory affairs and the need for reporting and consequences • 22:57
-
Emphasis on the effectiveness of old technology vaccines in preventing diseases like polio and tetanus • 23:49
Concerns raised about mRNA technology in vaccines and the need for regulatory action to address potential risks.
-
Vaccines work but may cause problems • 24:12
-
mRNA technology needs regulatory scrutiny • 24:18
-
Grandfathered technology poses future risks • 24:40
-
Legal challenges needed to address issues • 25:08
-
Focus on saving lives from potential fallout • 25:25
-
Importance of raising legal questions • 25:51
-
Continued discussion and action required • 26:22